Skip to content

Opus Genetics IRD Total Revenue

Total Revenue at other companies

AbbVie logo
AbbVieABBV
$15B+12.4%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$293K-84.8%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$3.05M+21,664%
Opko Health logo
Opko HealthOPK
$124.2M-17.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.61B+19.0%
Regenxbio logo
RegenxbioRGNX
$6.39M-92.8%

Other financials

Income statement

See full
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's total revenue?
Opus Genetics (IRD) reported total revenue of $2.16M in Q1 2026.
How has Opus Genetics's total revenue changed year-over-year?
Opus Genetics's total revenue decreased by 50.6% year-over-year, from $4.37M to $2.16M.
What is the long-term trend for Opus Genetics's total revenue?
Over 3 years (2022 to 2025), Opus Genetics's total revenue has grown at a -29.1% compound annual growth rate (CAGR), from $39.85M to $14.2M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.